Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.
Parkes EE, Savage KI, Lioe T, Boyd C, Halliday S, Walker SM, Lowry K, Knight L, Buckley NE, Grogan A, Logan GE, Clayton A, Hurwitz J, Kirk SJ, Xu J, Sidi FA, Humphries MP, Bingham V; Neo-DDIR Investigators; James JA, James CR, Paul Harkin D, Kennedy RD, McIntosh SA. Parkes EE, et al. Among authors: walker sm. Br J Cancer. 2022 Feb;126(2):247-258. doi: 10.1038/s41416-021-01599-0. Epub 2021 Nov 2. Br J Cancer. 2022. PMID: 34728791 Free PMC article.
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
Parkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, McCloskey KD, Buckley NE, Savage KI, Salto-Tellez M, McQuaid S, Harte MT, Mullan PB, Harkin DP, Kennedy RD. Parkes EE, et al. Among authors: walker sm. J Natl Cancer Inst. 2016 Oct 5;109(1):djw199. doi: 10.1093/jnci/djw199. Print 2017 Jan. J Natl Cancer Inst. 2016. PMID: 27707838 Free PMC article.
Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer.
Mulligan JM, Hill LA, Deharo S, Irwin G, Boyle D, Keating KE, Raji OY, McDyer FA, O'Brien E, Bylesjo M, Quinn JE, Lindor NM, Mullan PB, James CR, Walker SM, Kerr P, James J, Davison TS, Proutski V, Salto-Tellez M, Johnston PG, Couch FJ, Paul Harkin D, Kennedy RD. Mulligan JM, et al. Among authors: walker sm. J Natl Cancer Inst. 2014 Jan;106(1):djt335. doi: 10.1093/jnci/djt335. J Natl Cancer Inst. 2014. PMID: 24402422 Free PMC article.
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.
Turkington RC, Knight LA, Blayney JK, Secrier M, Douglas R, Parkes EE, Sutton EK, Stevenson L, McManus D, Halliday S, McCavigan AM, Logan GE, Walker SM, Steele CJ, Perner J, Bornschein J, MacRae S, Miremadi A, McCarron E, McQuaid S, Arthur K, James JA, Eatock MM, O'Neill R, Noble F, Underwood TJ, Harkin DP, Salto-Tellez M, Fitzgerald RC, Kennedy RD; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group. Turkington RC, et al. Among authors: walker sm. Gut. 2019 Nov;68(11):1918-1927. doi: 10.1136/gutjnl-2018-317624. Epub 2019 Mar 9. Gut. 2019. PMID: 30852560 Free PMC article.
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
Sharma P, Barlow WE, Godwin AK, Parkes EE, Knight LA, Walker SM, Kennedy RD, Harkin DP, Logan GE, Steele CJ, Lambe SM, Badve S, Gökmen-Polar Y, Pathak HB, Isakova K, Linden HM, Porter P, Pusztai L, Thompson AM, Tripathy D, Hortobagyi GN, Hayes DF. Sharma P, et al. Among authors: walker sm. J Clin Oncol. 2019 Dec 20;37(36):3484-3492. doi: 10.1200/JCO.19.00693. Epub 2019 Oct 28. J Clin Oncol. 2019. PMID: 31657982 Free PMC article.
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.
Malla SB, Fisher DJ, Domingo E, Blake A, Hassanieh S, Redmond KL, Richman SD, Youdell M, Walker SM, Logan GE, Chatzipli A, Amirkhah R, Humphries MP, Craig SG, McDermott U, Seymour MT, Morton DG, Quirke P, West NP, Salto-Tellez M, Kennedy RD, Johnston PG, Tomlinson I, Koelzer VH, Campo L, Kaplan RS, Longley DB, Lawler M, Maughan TS, Brown LC, Dunne PD; S:CORT consortium. Malla SB, et al. Among authors: walker sm. Clin Cancer Res. 2021 Jan 1;27(1):288-300. doi: 10.1158/1078-0432.CCR-20-3237. Epub 2020 Oct 7. Clin Cancer Res. 2021. PMID: 33028592 Free PMC article.
Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy.
Jain S, Lyons CA, Walker SM, McQuaid S, Hynes SO, Mitchell DM, Pang B, Logan GE, McCavigan AM, O'Rourke D, McArt DG, McDade SS, Mills IG, Prise KM, Knight LA, Steele CJ, Medlow PW, Berge V, Katz B, Loblaw DA, Harkin DP, James JA, O'Sullivan JM, Kennedy RD, Waugh DJ. Jain S, et al. Among authors: walker sm. Ann Oncol. 2018 Jan 1;29(1):215-222. doi: 10.1093/annonc/mdx637. Ann Oncol. 2018. PMID: 29045551 Free PMC article.
Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue.
Medlow PW, Steele CJ, McCavigan AM, Reardon W, Brown CM, Lambe SM, Ishiy FAA, Walker SM, Logan GE, Raji OY, Berge V, Katz B, Kay EW, Sheehan K, Watson RW, Harkin DP, Kennedy RD, Knight LA. Medlow PW, et al. Among authors: walker sm. BMC Med Genomics. 2018 Dec 27;11(1):125. doi: 10.1186/s12920-018-0442-y. BMC Med Genomics. 2018. PMID: 30591067 Free PMC article.
346 results